Secretome Therapeutics
PrivateLast Round
Series A
May 27, 2026
Total Funding Raised
$31.75M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Secretome Therapeutics is a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells to address cardiovascular diseases and inflammatory conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Secretome Therapeutics Comparables
Compare Secretome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunis, Inc. | 84% | |
| Remedy Cell Ltd. | 83% | |
| Micregen | 81% |
Secretome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 27, 2026 | ||||
| Grant | Mar 24, 2026 | ||||
| VC Round | Nov 25, 2024 | ||||
| Seed | Oct 17, 2019 |
Secretome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HEST Investments | VC Round |
| RA Capital Management | Series A |
| Parent Project Muscular Dystrophy | Grant |
| Abell Foundation | Seed |
| TEDCO | Seed |
| UM Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
Grew 41% QoQ from 17 to 24 employees.
- May 27, 2026
$30M round led by RA Capital Management
Recent news
Latest coverage and updates
- increases_headcount_byAug 4, 2026
Secretome Therapeutics, Inc. increased headcount by 4 on Jan 1st '26.
Secretome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Secretome Therapeutics's valuation, stock price, and market status.
Is Secretome Therapeutics a public or private company?
Secretome Therapeutics is a private company.
What is the current stock price of Secretome Therapeutics?
Secretome Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Secretome Therapeutics worth (valuation)?
Valuation information for Secretome Therapeutics is not publicly available.
Can I buy Secretome Therapeutics stock?
Secretome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Secretome Therapeutics's last funding round?
Secretome Therapeutics's most recent funding round was Series A on May 27, 2026.
Who are the main investors in Secretome Therapeutics?
Key investors in Secretome Therapeutics include HEST Investments, RA Capital Management, Abell Foundation.
Will Secretome Therapeutics IPO soon?
No public IPO plans have been announced for Secretome Therapeutics.
How can I track Secretome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Secretome Therapeutics's secondary market activity and sign up for updates.